NantKwest, Inc. (NASDAQ:NK) Files An 8-K Submission of Matters to a Vote of Security Holders

0

NantKwest, Inc. (NASDAQ:NK) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

Submission of Matters to a Vote of Security
Holders.

We held our 2017 annual meeting of stockholders on June9, 2017
(the Annual Meeting). Of the 82,155,862shares of our common stock
outstanding as of the record date of April17, 2017, 73,839,241
shares were represented at the Annual Meeting, either in person
or by proxy, constituting approximately 89.88% of the outstanding
shares of common stock. The matters voted on at the Annual
Meeting and the votes cast with respect to each such matter are
set forth below:

1. Election of Directors. Each of the following
nominees was elected to serve as a director, to hold office
until our 2018 annual meeting of stockholders and until his
respective successor has been duly elected and qualified
based on the following results of voting:

Nominee

Votes For VotesWithheld BrokerNon-Votes

Patrick Soon-Shiong

59,365,083 5,926,006 8,548,152

Barry J. Simon

59,282,537 6,008,552 8,548,152

Steve Gorlin

63,714,303 1,576,786 8,548,152

Michael D. Blaszyk

64,500,342 790,747 8,548,152

Richard Kusserow

64,325,607 965,482 8,548,152

John T. Potts, Jr.

64,410,791 880,298 8,548,152

John C. Thomas, Jr.

64,322,550 968,539 8,548,152
2. Ratification of Appointment of Independent Registered
Public Accounting Firm.
The appointment of Ernst
Young LLP as our independent registered public accounting
firm for the fiscal year ending December31, 2017 was ratified
based on the following results of voting:

For

Against

Abstentions

BrokerNon-Votes

73,606,884 220,389 11,968


About NantKwest, Inc. (NASDAQ:NK)

NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, non-hodgkin lymphoma and myelodysplastic syndrome.